Join
Live feed
·
PRReleasevia Quantisnow
Belite Bio Inc logo

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

ByQuantisnow·Wall Street's wire, on your screen.
BLTE· Belite Bio Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BLTE (Belite Bio Inc) and more on Quantisnow.